The aim of the study was to evaluate the therapeutic yield of intravenous iron for preoperative preparation of patients assigned for uterine myomectomy compared with oral iron therapy and to determine the value of supplemental erythropoietin therapy in resistant cases.
Introduction
Uterine fibroids are the most common type of tumor in the female reproductive system and the leading cause of hysterectomy. A population-based study in the USA found a cumulative incidence of uterine fibroids of greater than 66% on ultrasound examination in women approaching 50 years of age. A recent statistic from the Chinese Society of Health Management for nearly 500 000 adult Chinese women who had undergone health examinations during the year 2008 showed a prevalence of ultrasound-diagnosed uterine fibroids of 14.7% [1] [2] [3] .
Uterine fibroids may cause considerable symptoms, including menorrhagia, dysmenorrheal, and pelvic pain and pressure in some patients, necessitating surgical intervention. Treatment for uterine fibroids, however, is generally indicated only when symptoms are present and are severe enough to be unacceptable to the patient. There is no evidence that women with no symptoms or with mild symptoms benefit from intervention. Significant differences of hysterectomy rates for uterine fibroids between countries and among ethnic groups have been reported in numerous studies, raising questions of overused or underused medical care from the medical profession, implicating high subjectivity in decision making [4] [5] [6] [7] .
Myomectomy is the primary treatment modality for women with symptomatic leiomyomas who are of reproductive age and desire future fertility. Myomectomy can significantly improve symptoms and quality of life and, in some clinical situations, improve reproductive outcomes. There are robust surgical outcome data supporting the use of a minimally invasive approach such as laparoscopy and hysteroscopy over laparotomy. Perioperative outcomes and return to normal activity are significantly better with a minimally invasive approach. Reproductive outcomes are not adversely affected [7, 8] .
Leiomyomas can cause abnormal uterine bleeding and anemia, which may be acute if severe or chronic if recurrent, inducing iron deficiency anemia (IDA). Anemia was defined by the WHO as a hemoglobin concentration (Hb conc.) of less than 11 g/dl. Anemia is one of the world's leading causes of disability and thus one of the most serious global public health issues. Perioperative anemia endangers patients' outcome through imposed hemodynamic burden and deficient oxygen-carrying capacity and eventful wound-healing course. Several choices for iron replacement therapies exist, and increased pressure on budgets may require cheaper and effective preparations for improvement of iron stores within a short duration to achieve rapid preparation for surgery [9] [10] [11] .
The current study aimed to evaluate the therapeutic yield of intravenous iron therapy for preoperative preparation of patients assigned for uterine myomectomy in comparison with oral iron therapy and determine the value of supplemental erythropoietin therapy for resistant cases.
Patients and methods
The current prospective study was conducted at the Departments of Gynecology & Obstetrics and Clinical Pathology, Benha University Hospital, from January 2010 until January 2013. After approval of the study protocol by the local ethical committee and obtaining fully informed written consent from the patients, all women assigned for uterine myomectomy were enrolled in the study.
Exclusion criteria included anemia from causes other than iron deficiency, previous blood transfusion, hematological disease, intolerance to iron derivatives, recent administration of iron, and current usage of iron supplements. Patients with cardiovascular, renal or hepatic diseases, patients with suspicion of other gynecological lesions, patients with synchronous causes for manifest bleeding compromising iron stores, and those indicated for hysterectomy were also excluded from the study. Patients assigned for uterine myomectomy and had Hb conc. more than 10 mg/dl were not enrolled in the study.
All patients underwent full history taking including age, gravidity, parity, and number of living offspring. Menstrual history included duration and pattern of menstrual bleeding. All patients underwent completed gynecological examination, which included both abdominal and transvaginal uterine ultrasonography. All patients were prepared using oral contraceptive pills for hormonal control of bleeding to minimize blood loss and allow improvement of the general condition.
Patients were categorized according to grades of anemia into mild anemia if Hb conc. was more than 9-10 g/dl, moderate if was in the range of 7-9 g/dl, and severe if Hb conc. was less than 7 g/dl. Using sealed envelopes, patients were randomly allocated into two equal study groups according to the route of iron therapy administration: the intravenous group and the oral group. The intravenous group included patients assigned to receive intravenous iron therapy and the oral group included patients assigned to receive oral iron therapy.
In the intravenous group, the total iron dose in mg was calculated according to the following formula: patients' body weight (kg) Â Hb deficit [target Hb (g/dl) -actual Hb (g/dl)] + 500 of elemental iron to build up body iron stores. The resultant was rounded up to the nearest multiple of 100 to calculate the number of ampoules required [12] . Target Hb (g/dl) was set at 12 g/dl. In each infusion the maximum total dose administered was 200 mg elemental iron in 100 ml of normal saline infused over 20-30 min, given on alternate days. The preparation used was iron sucrose (IS) (Venofer; USP; American Regent, Inc., Shirley, New York, USA), which is brown, sterile, and aqueous and provided in 10 ml single-use vials containing 200 mg elemental iron. The ampoule was diluted with normal saline immediately before the infusion. No test dose was given. Treatment was completed after administration of the calculated dose.
The intravenous IS was chosen for its compositional properties as it is a complex of polynuclear iron(III) hydroxide cores that are superficially surrounded by a large number of noncovalently bound sucrose molecules resulting in a complex with a molecular mass of B60 000 Da, prohibiting renal elimination. The iron in the polynuclear cores is bound in a similar structure to that of physiologically occurring ferritin. The complex is stable and does not release ionic iron under physiological conditions. IS does not contain dextran; hence, chances of anaphylaxis are negligible. The rate of iron delivery to the marrow is a major factor in the regulation of marrow proliferation; IS has intermediate stability and strength, and is quickly cleared from the serum with a terminal half-life of B5-6 h and therefore is more rapidly available for erythropoiesis [13] [14] [15] .
In the oral group, women were instructed to take two tablets of ferrous bis-glycine sulfate complex (Ferrosanol Gyn; Chauvin/Minapharm, 6th October City, Cairo, Egypt; 454 mg + 1 mg folic acid) yielding 100 mg of elemental iron per day after meals. Ferrous bis-glycine chelate was chosen for its better iron bioavailability compared with ferrous sulfate, especially when the vehicles of consumption are foods that inhibit nonheme iron absorption. The ferrous bis-glycine sulfate complex is composed of two glycine molecules bound to a ferrous cation to form a double heterocyclic ring compound. This configuration protects the iron from dietary inhibitors and intestinal interactions, which explains its high bioavailability [16] . Absorption of amino-chelated iron correlated inversely with body iron stores [17] . In addition, vitamin C (Vitacid C effervescent tablets; CID Co., 6th October City, Cairo, Egypt) was given to enhance the bioavailability of iron from the bis-glycine chelate [18] . Vitamin C was given as an effervescent tablet, a form that enhances the absorption and metabolism of vitamin C when taken after meals as documented by the production company.
Treatment was completed on reaching the target Hb conc. of 12 g/dl, but Hb conc. of more than 10 g/dl was accepted for surgical interference and women approaching more than 10 g/dl were operated upon. All women who did not approach an Hb conc. of more than 10 g/dl within 4 weeks after commencement of iron therapy were shifted to a second-line therapy for 2 weeks that consisted of weekly subcutaneous injections of low-dose epoetin-a, up to a total dose of 600 IU/kg or more body weight plus oral iron therapy as assigned for the oral group.
Investigations
Venous blood samples were obtained at the time of enrollment and at 2, 4, and 6 weeks of intervention. Blood samples were obtained under complete aseptic conditions from the antecubital vein and were divided into two parts:
(1) The first part was collected in EDTA tubes (about 1.8 mg trik EDTA/1 ml blood) for estimation of Hb conc. using the cyanmethemoglobin method [19] . (2) The second part was kept in a plane container and left to clot. Then serum was separated by centrifugation at 3000 rpm for at least 5 min and stored at -201C until estimation of serum ferritin level using the ELISA kit (Eurogenetics, UK) and was based on a monoclonal antibody-sandwich technique to ensure optimal sensitivity and specificity [20] .
Results
The study included 60 women with a mean age of 30.2 ± 2.6 years (range: 26-37 years). The mean BMI of the studied women was 33.6 ± 2.3 kg/m 2 (range: 26.8-37 kg/m 2 ): five women were of average weight, 35 women were obese, and 20 women were morbidly obese. All enrolled women were multipara with mean gravidity rate of 1.9 ± 0.7 and mean parity rate of 1.5 ± 0.7 (range: 0-3). Three women had no living offspring, 29 women had one living offspring, 24 women had two living offspring, and four women had three living offspring. There was a nonsignificant (P40.05) difference between the studied groups as regards enrollment (Table 1) .
Mean duration of disease was 10.8 ± 2.3 months (range: 6-16 months). However, the majority of patients had disease duration of less than 12 months. The mean length of the menstrual cycle was 25.9 ± 2.3 days (range: 21-30 days) and the mean duration of menstrual bleeding was 8.1 ± 1.7 days (range: 6-12 days). Ultrasonographic examination detected 45 submucous fibroids, 10 interstitial fibroids, and five subserous fibroids; only seven cases had small multiple myomata. The largest mean diameter of the detected myoma was 7.8 ± 1.2 cm (range: 6-11 cm). There was a nonsignificant (P40.05) difference in disease-related data between the studied groups (Tables 2 and 3 ).
At the time of enrollment in the study (baseline) 12 women had mild anemia, 41 patients had moderate anemia, and seven women had severe anemia with nonsignificant (P40.05) difference between the study groups. Both lines of therapy induced significant (Po0.05) progressive increase in Hb conc. until the end of 4 weeks of therapy, at which time no patient had severe anemia, 17 patients had moderate anemia, and 15 patients had Hb conc. in the range of more than 9-10, 23 patients had Hb conc. in the range of more than 10-11, and five patients had Hb conc. of more than 11, with significant (Po0.05) difference in favor of the intravenous group. Thirty-three patients -11 in the intravenous group and 22 in the oral group -received epoetin-a and oral iron therapy for 2 weeks, which induced an increase in Hb conc., wherein 10 patients had Hb conc. in the range of more than 9-10, 20 patients had Hb conc. in the range of more than 10-11, and two patients had Hb conc. of more than 11. Only one patient in the oral group required blood transfusion for correction of anemia.
The mean baseline Hb conc. showed nonsignificant (P40.05) difference between the two study groups. Both groups showed steady, progressive and significant (Po0.05) increase in Hb conc. with concomitant significant (Po0.05) decrease in concentration deficit. Patients in the intravenous group had significantly higher (P = 0.034) Hb conc. at week 2 compared with patients in the oral group, and the difference showed higher significance (P = 0.001) at 4 weeks of therapy. Moreover, intravenous therapy yielded improvement that manifested as significantly lower frequency of patients requiring epoetin-a therapy compared with patients of group oral (Table 4 and Fig. 1 ).
Mean baseline serum ferritin levels were nonsignificantly (P40.05) different between the study groups. Both groups showed steady, progressive, significant (Po0.05) increase in serum ferritin levels with significantly higher serum ferritin levels in the intravenous group compared with the oral group throughout the study period. At week 2, serum ferritin level was significantly (Po0.05) higher compared with baseline level in both groups. At week 4, serum ferritin level was significantly (Po0.05) higher compared with both baseline and week 2 levels in both groups. At week 6, the estimated serum ferritin level was significantly (Po0.05) higher in the oral group but nonsignificantly (P40.05) higher in the intravenous group compared with week 4 levels, despite the significantly higher levels in both groups compared with baseline and week 2 levels (Table 5 and Fig. 2 ).
Discussion
The current study aimed for rapid preparation of patients with IDA secondary to bleeding uterine myoma and assigned for myomectomy; both intravenous and oral iron therapy led to significant improvement of anemia and elevation of Hb conc. with concomitant significant decrease in concentration deficit and significant increase Data are presented as mean ± SD and numbers; ranges and percentages are given in parentheses. Data are presented as mean ± SD and numbers; ranges and percentages are given in parentheses.
in iron stores manifested as significant increase in serum ferritin. Intravenous iron therapy was more beneficial than oral therapy, as manifested by the significantly higher Hb conc. and serum ferritin compared with oral therapy. Moreover, intravenous therapy significantly reduced the frequency of resistant cases requiring erythropoietin therapy.
The obtained results coincided with recent studies based on comparison between intravenous and oral iron replacement Data are presented as n (%). Data are presented as mean ± SD and numbers; ranges and percentages are given in parenthesis. Data are presented as mean ± SD and numbers; ranges and percentages are given in parenthesis. therapies. Shafi et al. [21] compared the efficacy and safety of intravenous iron with oral iron in the treatment of IDA during pregnancy and found that intravenous iron elevates Hb and restores iron stores faster than does oral iron, with no severe adverse reactions. Neeru et al. [22] found intravenous IS to be safe and effective in the treatment of IDA during pregnancy and iron stores increased better with intravenous compared with oral iron. Froessler et al. [23] compared oral with intravenous iron administration in women in late pregnancy and/or after labor to correct iron deficiency and found both forms of iron replacement therapy to lead to increased Hb and ferritin levels over the testing period; however, they found that ferritin was significantly higher in the intravenous iron group compared with the oral iron group and concluded that intravenous and oral irons were both effective in correcting peripartum anemia, although intravenous iron restored stores faster than oral iron. Kochhar et al. [24] found a statistically significant difference in the increase of Hb and ferritin levels between intravenous and oral iron therapies on day 30 and concluded that intravenous administration of IS is a safe treatment for correction of anemia in pregnancy, without serious side effects.
There are several studies supporting the efficacy of intravenous iron replacement therapy in various disease states associated with IDA: Chen et al. [25] found the use of intravenous iron in a fractionated way to be effective in the correction of severe anemia in rheumatoid arthritis patients, especially in those with nonstainable iron marrow. Shrivastava et al. [26] reported significant progressive increases in Hb conc. with 3 weeks of intravenous IS therapy with a decline in the rate of blood transfusion among total anemic women in the peripartum period in rural areas. Dewan et al. [27] found that intravenous IS was a safe and effective mode of treatment for the rapid reversal of IDA in obstetric and gynecological settings, and Gomollón and Gisbert [28] reported that oral iron is not an ideal option for treating anemia and iron deficiency in inflammatory bowel diseases but that intravenous iron should be preferred in at least five scenarios: intolerance to oral iron, severe anemia, failure of oral therapy, need for quick recovery, and use of erythropoietin.
In line with the used policies for preoperative preparation, Cladellas et al. [29] found that administration of combined therapy of recombinant human erythropoietin and intravenous IS supplementation for preoperative preparation for valve replacement surgery was independently associated with decreased postoperative morbidity and in-hospital mortality and that individually this treatment also decreased postoperative renal failure and rate of blood transfusion and shortened hospitalization.
With regard to the iron preparations used, the use of intravenous IS has been proven to be effective therapy by studies comparing various intravenous iron preparations: Dillon et al. [30] compared three preparations of intravenous iron -iron dextran (ID), IS, and iron carboxymaltose (ICM) -and reported significantly higher Hb gain with IS and ICM than with ID, with nonsignificant difference between IS and ICM; however, ICM was three times more expensive than IS. Pfenniger et al. [31] compared the safety and efficacy of intravenous high-dose ICM with IS for the treatment of postpartum anemia and reported the following: intravenous ICM is as safe as IS in the management of postpartum IDA despite five times higher dosage; both drugs are effective and offer a rapid normalization of Hb after delivery; and the single advantage of ICM was the lower incidence of side effects at the injection site, a shorter treatment period, and better patient compliance.
In group oral, ferrous bis-glycine sulfate complex was given after meals and was combined with vitamin C supplements to enhance its absorption, in line with such policy; Binaghi et al. [32] found that orange-based artificial drinks significantly increased iron dialyzability, whereas tea and milk decreased it significantly.
In support of the efficacy of ferrous bis-glycine sulfate complex received by patients of group oral, Dos Santos et al. [33] compared the effectiveness of ferrous sulfate and ferrous bis-glycine sulfate complex for treatment of children with IDA and reported that the interventions showed a significant increase in Hb levels and serum ferritin concentrations after 8 weeks with nonsignificance difference in the intergroup comparison. Also, Ferrari et al. [34] reported significant increase of Hb and ferritin values after 2 months of treatment of cancer patients with IDA using ferrous bisglycine sulfate complex and with no significant difference compared with ferrous sulfate preparation, but with significant reduction in the frequency of adverse reactions.
It could be concluded that intravenous iron therapy allows rapid and efficient alleviation of anemia and spares the need and cost of erythropoietin therapy. Combination of oral iron and erythropoietin allowed resistant cases to approach the operative target Hb conc. and could be preserved as second-line therapy for resistant anemia and as first-line therapy for patients intolerant to intravenous iron therapy.
